

**REMARKS**

Applicants acknowledge that the Amendment of August 9, 2010 has been entered. Claims 153-169 are pending, claims 1-152 are cancelled and claim 170 is newly added via this supplemental amendment, all without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

No new matter is added.

Support for newly added claim 170 can be found throughout the application, including for example, in the substitute specification filed on August 9, 2010, specifically in Example 12, directed to human erythropoietin produced in insect cells of the present invention; on page 14, paragraphs 1 and 4, directed to insect cells that grow in serum-free media; page 14, paragraph 5 and page 15, paragraphs 1 and 2, directed to a method of using insect cells that grow in serum-free media to produce recombinant baculovirus and recombinant gene products and page 26, paragraph 4, directed to the use of a baculovirus expression system comprising a nucleic acid molecule (preferably encoding an expression product comprising an epitope or antigen) to infect insect cells that grow in serum-free media.

It is submitted that these claims are in full compliance with the requirements of 35 U.S.C. § 112. The amendments to the claims and the remarks herein are not made for the purpose of patentability within the meaning of 35 U.S.C. §§ 101, 102, 103 or 112; but rather the amendments and remarks are made simply for clarification and to round out the scope of protection to which Applicants are entitled.